Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Various tumor antigens can be loaded onto dendritic cells (DCs) to induce a potent cytotoxic T lymphocyte (CTL) response in DC-based immunotherapy against breast cancer. However, in the clinical setting, obtaining a sufficient number of autologous tumor cells as a source of tumor antigens is a laborious process. We therefore investigated the feasibility of immunotherapy using breast-cancer-specific CTLs generated in vitro by use of alpha-type 1 polarized DCs (αDC1s) loaded with ultraviolet B-irradiated cells of the breast cancer cell line MCF-7. Materials and Methods αDC1s were induced by loading allogeneic tumor antigen generated from the MCF-7 UVBirradiated breast cancer cell line. Antigen-pulsed αDC1s were evaluated by morphological and functional assays, and the breast-cancer-specific CTL response was analyzed by cytotoxic assay. Results The αDC1s significantly increased the expression of several molecules related to DC maturation without differences according to whether the αDC1s were loaded with tumor antigens. The αDC1s showed a high production of interleukin-12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumor antigens. Breast-cancer-specific CTLs against autologous breast cancer cells were successfully induced by αDC1s loaded with apoptotic MCF-7 cells. Conclusion Autologous DCs loaded with an allogeneic breast cancer cell line can generate potent breast-cancer-specific CTL responses. This may be a practical method for cellular immunotherapy in patients with breast cancer.
Abstract
Purpose Various tumor antigens can be loaded onto dendritic cells (DCs) to induce a potent cytotoxic T lymphocyte (CTL) response in DC-based immunotherapy against breast cancer. However, in the clinical setting, obtaining a sufficient number of autologous tumor cells as a source of tumor antigens is a laborious process. We therefore investigated the feasibility of immunotherapy using breast-cancer-specific CTLs generated in vitro by use of alpha-type 1 polarized DCs (αDC1s) loaded with ultraviolet B-irradiated cells of the breast cancer cell line MCF-7. Materials and Methods αDC1s were induced by loading allogeneic tumor antigen generated from the MCF-7 UVBirradiated breast cancer cell line. Antigen-pulsed αDC1s were evaluated by morphological and functional assays, and the breast-cancer-specific CTL response was analyzed by cytotoxic assay. Results The αDC1s significantly increased the expression of several molecules related to DC maturation without differences according to whether the αDC1s were loaded with tumor antigens. The αDC1s showed a high production of interleukin-12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumor antigens. Breast-cancer-specific CTLs against autologous breast cancer cells were successfully induced by αDC1s loaded with apoptotic MCF-7 cells. Conclusion Autologous DCs loaded with an allogeneic breast cancer cell line can generate potent breast-cancer-specific CTL responses. This may be a practical method for cellular immunotherapy in patients with breast cancer.
참고문헌 (25)
- Gloeckler Ries LA, "Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program", Oncologist, 8, pp.541~552 (2003)
- Anderson KS, "Tumor vaccines for breast cancer", Cancer Invest, 27, pp.361~368 (2009)
- Curigliano G, "Vaccine immunotherapy in breast cancer treatment: promising, but still early", Expert Rev Anticancer Ther, 7, pp.1225~1241 (2007)
- Chaudhuri S, "Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles", Proc Natl Acad Sci U S A, 97, pp.11451~11454 (2000)
- Disis ML, "Existent Tcell and antibody immunity to HER-2", neu protein in patients with breast cancer, 1994, pp.54, 16~20
- Jerome KR, "Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA", J Immunol, 151, pp.1654~1662 (1993)
- Carella AM, "Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer", Lancet, 366, pp.318~320 (2005)
- Banchereau J, "Dendritic cells and the control of immunity", Nature, 392, pp.245~252 (1998)
- Reid DC, "Dendritic cells and immunotherapy for malignant disease", Br J Haematol, 112, pp.874~887 (2001)
- Mailliard RB, "Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity", Cancer Res, 64, pp.5934~5937 (2004)
- Lee JJ, "Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia", J Leukoc Biol, 84, pp.319~325 (2008)
- Gilewski T, "Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21", Clin Cancer Res, 6, pp.1693~1701 (2000)
- Murray JL, "Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75(369-377) combined with granulocyte macrophage colony-stimulating factor in HLAA2+ patients with metastatic breast and ovarian cancer", Clin Cancer Res, 8, pp.3407~3418 (2002)
- Parkhurst MR, "Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase", Clin Cancer Res, 10, pp.4688~4698 (2004)
- Raje N, "Tumour cell", dendritic cell fusions as a vaccination strategy for multiple myeloma, 2004, pp.125, 343~352
- Lee JJ, "Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates", LEUKEMIA & LYMPHOMA, 48(10), pp.2022~2031 (2007), HARWOOD ACAD PUBL GMBH
- Palucka AK, "Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity", J Immunother, 29, pp.545~557 (2006)
- Muthuswamy R, "Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation", Cancer Res, 68, pp.5972~5978 (2008)
- Takei M, "Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization", Biochem Pharmacol, 68, pp.441~452 (2004)
- Trepiakas R, "Comparison of alpha-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients", Vaccine, 26, pp.2824~2832 (2008)
- Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
- Porter DA, "A SAGE (serial analysis of gene expression) view of breast tumor progression", Cancer Res, 61, pp.5697~5702 (2001)
- Matsumoto S, "Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+ T cells", Cancer Immunol Immunother, 55, pp.131~139 (2006)
- Delirezh N, "Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro", Cell Immunol, 257, pp.23~31 (2009)
- Salcedo M, "Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate", Cancer Immunol Immunother, 55, pp.819~829 (2006)